Diagnose Events Healthcare Patient-Centered 
GeriPal
DECEMBER 2, 2022
She directs UCSF MERI’s patient, family, and clinician support with classes and consultation on resiliency, well-being, and grief. You wrote about how when it comes to talking about patients with dementia, they’re rarely portrayed as resilient. And the person with dementia, the patient, said yes. How do we move on?
GeriPal
OCTOBER 13, 2022
When I’m on service these days there is inevitably a moment when a resident says “Patient so-and-so is on X” – and I have absolutely no idea what X is. It’s Lona Mody who is a translational infectious disease researcher at the University of Michigan and VA Ann Arbor Healthcare System. Summary Transcript Summary.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeriPal
OCTOBER 17, 2024
We talk about what is heart failure, particularly HFpEF, how we treat it (including the use of sodium–glucose cotransporter-2 inhibitors (SGLT2’s), and how we should apply guidelines to individual patients, especially those with multimorbidity who are taking a lot of other medications. When I see a patient? Matthew, I get the lyrics.
New South Family Medicine and MedSpa
NOVEMBER 24, 2022
Direct primary care offers you and your family top-notch health care, and so much more.like a high patient and provider satisfaction with an improved quality of care. Providers at New South Family Medicine and MedSpa can address the patient's deeper needs, rather than trying to rush through a hectic day full of too-brief appointments.
GeriPal
OCTOBER 20, 2022
And, who within ASPE guides aging policy and connects policy to every day health challenges experienced by patients and clinicians? It’s Lona Mody who is a translational infectious disease researcher at the University of Michigan and VA Ann Arbor Healthcare System. difficile that patients are exposed to and antibiotic resistance.
GeriPal
AUGUST 17, 2023
However, as noted in our editorial published with the donanemab trial , the modest benefits of amyloid antibodies would likely not be questioned by patients, clinicians, or payers if amyloid antibodies were low risk, inexpensive, and simple to administer. However, they are none of these. Welcome back to the GeriPal podcast, Jason.
GeriPal
JANUARY 26, 2023
I think that, as Ramona will talk about and elucidate a bit further, is just a recognition that in this country we have traditionally, and to my mind continue to do so, cause serious harm to Black people, that you can see that play out within healthcare in ways that are both big and small. Eric: Absolutely. I was going to stop at that point.
Expert insights. Personalized for you.
101 
Let's personalize your content